AC Ventures

AC Ventures is one of Indonesia’s most active early-stage venture firms, headquartered in Jakarta and writing Seed, Series A, and Series B checks in the $1M to $5M range. The fund’s positioning is broad across Indonesian digital ecosystem disruptors, with healthcare relevance concentrated in digital health platforms targeting Indonesian consumers and SME healthcare providers, telemedicine, pharmacy and clinic SaaS, and AI applications layered onto Indonesian clinical and insurance data. Founders pursuing biotech, devices with multi-year clearance pathways, or care delivery brick-and-mortar should look at specialist Indonesian PE. The right founder is an Indonesian technical or commercial operator building a category-leading platform with credible unit economics in the world’s fourth-largest population, where healthcare access and insurance reform under BPJS Kesehatan continue to drive demand for tech-enabled solutions. Geographic advantage is real and meaningful. AC Ventures has one of the deeper Indonesian operator networks among Tier-1 Indonesian funds, sees most early-stage Indonesian deals, and has historically syndicated with East Ventures, Alpha JWC, and Openspace at Series A and Series B. The fund’s portfolio breadth across consumer, fintech, and digital health gives it pattern recognition for Indonesian go-to-market that pure global funds cannot match. Best entry is a warm intro from a portfolio founder, a Jakarta-based operator in the ecosystem, or a regional co-investor. Lead the pitch with revenue, cohort retention in Bahasa Indonesia and across Indonesian islands, and a sober view on the operating reality that Indonesia is fragmented across thousands of islands and many provincial regulators. Be explicit about BPJS dynamics where relevant, data residency under PDP Law, and how the product handles infrastructure variability across markets. AI healthcare founders should describe Bahasa Indonesia model performance and clinical or operational integration cycles. Caveats: at $1M to $5M, AC Ventures can lead Series A but typically co-leads larger rounds, so founders should clarify the lead structure early. Indonesian healthcare regulator unpredictability is a recurring theme, and savvy investors model regulatory change carefully. Ask the fund about reserves, prorata behavior, and which Series B and C leads have followed it into healthcare portfolio companies. Reference checks with current portfolio CEOs on operating support and regulator navigation are particularly worth the time. Used appropriately, AC Ventures is one of the most credible Indonesian early-stage partners for healthcare and digital founders building toward category leadership.